Type 2 Diabetes Pharmacotherapy De-Escalation Through AI-Enabled Lifestyle Modifications: A Randomized Clinical Trial
NEJM Catalyst · 20.08.2025 · 6 (9)
DOI: 10.1056/cat.25.0016 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift NEJM Catalyst, erschienen am 20.08.2025. Verfasst von Kevin M. Pantalone und 12 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pantalone, K. M., Xiao, H., Bena, J., Morrison, S., Downie, S., Boyd, A. M., Shah, L., Willis, B., Beharry-Diaz, J., Milinovich, A., Joshi, S., Kaufman, F. R., & Mechanick, J. I. (2025). Type 2 Diabetes Pharmacotherapy De-Escalation Through AI-Enabled Lifestyle Modifications: A Randomized Clinical Trial. NEJM Catalyst, 6(9). https://doi.org/10.1056/cat.25.0016
Vancouver
Pantalone KM, Xiao H, Bena J, Morrison S, Downie S, Boyd AM, et al. Type 2 Diabetes Pharmacotherapy De-Escalation Through AI-Enabled Lifestyle Modifications: A Randomized Clinical Trial. NEJM Catalyst. 2025;6(9). doi:10.1056/cat.25.0016
BibTeX
@article{Pantalone2025,
author = {Pantalone, Kevin M. and Xiao, Huijun and Bena, James and Morrison, Shannon and Downie, Shannon and Boyd, Ana Maria and Shah, Lisa and Willis, Bree and Beharry-Diaz, Jewel and Milinovich, Alex and Joshi, Shashank and Kaufman, Francine R. and Mechanick, Jeffrey I.},
title = {Type 2 Diabetes Pharmacotherapy De-Escalation Through AI-Enabled Lifestyle Modifications: A Randomized Clinical Trial},
journal = {NEJM Catalyst},
year = {2025},
volume = {6},
number = {9},
doi = {10.1056/cat.25.0016}
}
EUVIMED